DiaMedica Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

DiaMedica Therapeutics

04/11/2023 03:02

* DiaMedica Therapeutics Inc  DMAC.OQ   DMAC.O  is expected
to show no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for DiaMedica
Therapeutics
Inc is for a loss of 13 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for DiaMedica
Therapeutics Inc is $7​, above​ its last closing price of $2.54.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.19       -0.18      -0.16     Beat    9.4
 Mar. 31 2023  -0.15       -0.16      -0.20     Missed  -25
 Dec. 31 2022              -0.14      -0.14     Met     0​
 Sep. 30 2022  -0.13       -0.15      -0.12     Beat    18.6
 ​​Jun.        -0.17       -0.18      -0.13     Beat    27.8
 30 2022                                                
 Mar. 31 2022  -0.16       -0.21      -0.13     Beat    39.1​
 Dec. 31 2021              -0.18      -0.10     Beat    43.2
 Sep. 30 2021  -0.21       -0.23      -0.18     Beat    21.1
 This summary was machine generated November 4 at 03:01 GMT.  All
figures in US dollars  unless otherwise stated